INR 1764.95
(0.06%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 13.33 Billion INR | 5.36% |
2022 | 12.08 Billion INR | -26.79% |
2021 | 17.34 Billion INR | 20.29% |
2020 | 14.37 Billion INR | 33.29% |
2019 | 10.94 Billion INR | 38.12% |
2018 | 7.72 Billion INR | 33.55% |
2017 | 5.84 Billion INR | -7.54% |
2016 | 6.32 Billion INR | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | 2.64 Billion INR | -21.2% |
2024 Q2 | 3.56 Billion INR | 12.95% |
2023 FY | - INR | 5.36% |
2023 Q2 | 3.77 Billion INR | 13.8% |
2023 Q3 | 3.93 Billion INR | 4.39% |
2023 Q1 | 3.31 Billion INR | 119.69% |
2023 Q4 | 3.58 Billion INR | -8.92% |
2022 Q1 | 3.44 Billion INR | -16.38% |
2022 FY | - INR | -26.79% |
2022 Q4 | 1.5 Billion INR | -57.02% |
2022 Q3 | 3.51 Billion INR | -3.14% |
2022 Q2 | 3.62 Billion INR | 5.27% |
2021 FY | - INR | 20.29% |
2021 Q4 | 4.11 Billion INR | 4.35% |
2021 Q3 | 3.94 Billion INR | -7.76% |
2021 Q2 | 4.27 Billion INR | -14.12% |
2021 Q1 | 4.98 Billion INR | 33.05% |
2020 Q1 | 4.44 Billion INR | 55.97% |
2020 Q2 | 3.18 Billion INR | -28.48% |
2020 Q3 | 2.99 Billion INR | -5.88% |
2020 FY | - INR | 33.29% |
2020 Q4 | 3.74 Billion INR | 25.06% |
2019 FY | - INR | 38.12% |
2019 Q4 | 2.85 Billion INR | 20.28% |
2019 Q3 | 2.37 Billion INR | 0.0% |
2019 Q1 | 2.79 Billion INR | 0.0% |
2018 FY | - INR | 33.55% |
2017 FY | - INR | -7.54% |
2016 FY | - INR | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Abbott India Limited | 16.97 Billion INR | 21.482% |
Cipla Limited | 67.19 Billion INR | 80.161% |
GlaxoSmithKline Pharmaceuticals Limited | 8.87 Billion INR | -50.24% |
Kopran Limited | 744.13 Million INR | -1691.437% |
Marksans Pharma Limited | 4.58 Billion INR | -190.698% |
NGL Fine-Chem Limited | 678.68 Million INR | -1864.197% |
Pfizer Limited | 8.23 Billion INR | -61.824% |
Sanofi India Limited | 8.86 Billion INR | -50.324% |
SMS Pharmaceuticals Limited | 1.21 Billion INR | -1000.992% |
TTK Healthcare Limited | 999.34 Million INR | -1233.947% |